Dr Adam Ryan Zink, PHARMD | |
101 W Rochester St, Akron, IN 46910-9997 | |
(574) 893-4413 | |
Not Available |
Full Name | Dr Adam Ryan Zink |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 101 W Rochester St, Akron, Indiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1619058633 | NPI | - | NPPES |
100295900 | Medicaid | IN | |
1506469 | Other | IN | NABP NUMBER |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 26020169A (Indiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Adam Ryan Zink, PHARMD 3285 Manitou Park Rd, Rochester, IN 46975-8955 Ph: (574) 223-6956 | Dr Adam Ryan Zink, PHARMD 101 W Rochester St, Akron, IN 46910-9997 Ph: (574) 893-4413 |
News Archive
The mosquito-borne Zika virus linked to microcephaly and other neurological problems in newborns of affected mothers directly infects the brain progenitor cells destined to become neurons, UT Southwestern Medical Center researchers report in a study published online today in Cell Reports.
UC San Diego Health System and Scripps Health are partnering to provide improved continuity of patient care, fellowship training and research in hospice and palliative medicine. Under a new five-year agreement, Scripps will work with UC San Diego to provide outpatient and inpatient hospice care for UC San Diego patients, allowing UC San Diego physicians to better coordinate post-acute care for patients with chronic illness.
Up to now, adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease usually continued their conventional androgen deprivation therapy (ADT) while the cancer was observed for the occurrence of metastases (so-called watchful waiting).
Tyco International Ltd. today reported $0.55 in diluted earnings per share (EPS) from continuing operations for the fiscal fourth quarter of 2010 and diluted EPS from continuing operations before special items of $0.74 per share. Revenue in the quarter was $4.5 billion with organic revenue growth of 2% year-over-year. Cash from operating activities was $963 million and free cash flow was $598 million. These amounts included $39 million of cash outflows related to restructuring activities and acquisition-related costs.
Neural stem cells generate new neurons throughout life in the mammalian brain. However, with advancing age the potential for regeneration in the brain dramatically declines.
› Verified 5 days ago